《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读

2021-10-20 国家重大公共卫生事件医学中心华中科技大学同济医学院附属同济医院感染科中国医学前沿杂志(电子版)

本文就该指导意见进行全方位的解读,并与APASL、欧洲肝病协会、美国肝病研究协会和中华医学会感染病学分会/肝病学分会等慢性乙型肝炎诊疗威廉亚洲博彩公司建议的停药标准进行比较。

中文标题：

发布机构：

国家重大公共卫生事件医学中心华中科技大学同济医学院附属同济医院感染科

发布日期：

2021-10-20

简要介绍：

2021年7月23日,亚太地区肝病协会(Asian Pacific Association for the Study of Liver Diseases,APASL)在其官方杂志Hepatology International上全文发表了《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》,提出了慢性乙型肝炎患者长期核苷(酸)类似物治疗的停药标准、停药策略、预测复发、停药后随访策略等建议,也讨论了停药前评估和停药后再治疗等方案。对符合停药标准的患者采用合适的停药策略,通过预测复发、密切随访和积极再治疗减少因临床复发而发生肝功能失代偿和肝衰竭的概率,力争达到乙型肝炎表面抗原转阴的"功能性治愈",实现安全停药。本文就该指导意见进行全方位的解读,并与APASL、欧洲肝病协会、美国肝病研究协会和中华医学会感染病学分会/肝病学分会等慢性乙型肝炎诊疗威廉亚洲博彩公司建议的停药标准进行比较。各威廉亚洲博彩公司的停药标准根据地区差异不尽相同,期待通过进一步的研究制定更加完善、个体化的停药共识或威廉亚洲博彩公司。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=f76341c0022e651d, title=《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读, enTitle=, guiderFrom=中国医学前沿杂志(电子版), authorId=0, author=, summary=本文就该指导意见进行全方位的解读,并与APASL、欧洲肝病协会、美国肝病研究协会和中华医学会感染病学分会/肝病学分会等慢性乙型肝炎诊疗威廉亚洲博彩公司建议的停药标准进行比较。, cover=, journalId=0, articlesId=null, associationId=2166, associationName=国家重大公共卫生事件医学中心华中科技大学同济医学院附属同济医院感染科, associationIntro=国家重大公共卫生事件医学中心华中科技大学同济医学院附属同济医院感染科, copyright=0, guiderPublishedTime=Wed Oct 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">2021年7月23日,亚太地区肝病协会(Asian Pacific Association for the Study of Liver Diseases,APASL)在其官方杂志Hepatology International上全文发表了《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》,提出了慢性乙型肝炎患者长期核苷(酸)类似物治疗的停药标准、停药策略、预测复发、停药后随访策略等建议,也讨论了停药前评估和停药后再治疗等方案。对符合停药标准的患者采用合适的停药策略,通过预测复发、密切随访和积极再治疗减少因临床复发而发生肝功能失代偿和肝衰竭的概率,力争达到乙型肝炎表面抗原转阴的"功能性治愈",实现安全停药。本文就该指导意见进行全方位的解读,并与APASL、欧洲肝病协会、美国肝病研究协会和中华医学会感染病学分会/肝病学分会等慢性乙型肝炎诊疗威廉亚洲博彩公司建议的停药标准进行比较。各威廉亚洲博彩公司的停药标准根据地区差异不尽相同,期待通过进一步的研究制定更加完善、个体化的停药共识或威廉亚洲博彩公司。</span></p>, tagList=[TagDto(tagId=2629, tagName=慢性乙型肝炎), TagDto(tagId=6634, tagName=肝脏疾病), TagDto(tagId=118708, tagName=病毒性肝炎组)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=85, categoryName=威廉亚洲博彩公司 &解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2629, guiderKeyword=慢性乙型肝炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=258080, appHits=85, showAppHits=0, pcHits=651, showPcHits=257994, likes=1, shares=9, comments=5, approvalStatus=1, publishedTime=Mon Nov 29 14:50:55 CST 2021, publishedTimeString=2021-10-20, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 29 14:50:35 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 22:47:09 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_APASL慢性乙型肝炎患者停用核苷_酸_类似物指导意见_解读.pdf)])

_APASL慢性乙型肝炎患者停用核苷_酸_类似物指导意见_解读.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1082353, encodeId=0be31082353c6, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077830, encodeId=b15010e7830ff, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d2c5567444, createdName=ms5000001569808384, createdTime=Tue Dec 07 19:14:12 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077247, encodeId=313010e7247c3, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=穆新, createdTime=Mon Dec 06 08:50:14 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075282, encodeId=f6d810e52825a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:01:10 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075244, encodeId=0d4310e5244dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35305534934, createdName=寒寒子, createdTime=Mon Nov 29 23:20:55 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
2021-12-21 龙珠

学习好资料！

150 0
[GetPortalCommentsPageByObjectIdResponse(id=1082353, encodeId=0be31082353c6, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077830, encodeId=b15010e7830ff, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d2c5567444, createdName=ms5000001569808384, createdTime=Tue Dec 07 19:14:12 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077247, encodeId=313010e7247c3, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=穆新, createdTime=Mon Dec 06 08:50:14 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075282, encodeId=f6d810e52825a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:01:10 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075244, encodeId=0d4310e5244dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35305534934, createdName=寒寒子, createdTime=Mon Nov 29 23:20:55 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
2021-12-07 ms5000001569808384

学习

161 0
[GetPortalCommentsPageByObjectIdResponse(id=1082353, encodeId=0be31082353c6, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077830, encodeId=b15010e7830ff, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d2c5567444, createdName=ms5000001569808384, createdTime=Tue Dec 07 19:14:12 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077247, encodeId=313010e7247c3, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=穆新, createdTime=Mon Dec 06 08:50:14 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075282, encodeId=f6d810e52825a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:01:10 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075244, encodeId=0d4310e5244dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35305534934, createdName=寒寒子, createdTime=Mon Nov 29 23:20:55 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
2021-12-06 穆新

非常感谢！

178 0
[GetPortalCommentsPageByObjectIdResponse(id=1082353, encodeId=0be31082353c6, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077830, encodeId=b15010e7830ff, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d2c5567444, createdName=ms5000001569808384, createdTime=Tue Dec 07 19:14:12 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077247, encodeId=313010e7247c3, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=穆新, createdTime=Mon Dec 06 08:50:14 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075282, encodeId=f6d810e52825a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:01:10 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075244, encodeId=0d4310e5244dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35305534934, createdName=寒寒子, createdTime=Mon Nov 29 23:20:55 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
2021-11-30 微探

学习学习

170 0
[GetPortalCommentsPageByObjectIdResponse(id=1082353, encodeId=0be31082353c6, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:40:05 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077830, encodeId=b15010e7830ff, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d2c5567444, createdName=ms5000001569808384, createdTime=Tue Dec 07 19:14:12 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077247, encodeId=313010e7247c3, content=非常感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=穆新, createdTime=Mon Dec 06 08:50:14 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075282, encodeId=f6d810e52825a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:01:10 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075244, encodeId=0d4310e5244dc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35305534934, createdName=寒寒子, createdTime=Mon Nov 29 23:20:55 CST 2021, time=2021-11-29, status=1, ipAttribution=)]
2021-11-29 寒寒子

学习

185 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化威廉亚洲博彩公司

《APASL慢性乙型肝炎患者停用核苷(酸)类似物指导意见》解读

相关威廉亚洲博彩公司

拓展阅读

科室

工具

服务